Washington, DC 20006-5349
HELPLINE
For decades, mesothelioma has been widely understood as a disease that primarily affects older men with a history of occupational asbestos exposure. While this remains true in many cases, emerging research is challenging that long-held perception and expanding what both patients and healthcare providers should know about this rare and aggressive cancer. Each year, approximately…
Vivace Therapeutics, a company that develops cancer treatments, announced on July 30, 2025, that the U.S. Food and Drug Administration (FDA) has granted its experimental drug, VT3989, an “Orphan Drug Designation” (ODD) to treat mesothelioma, a rare and aggressive form of cancer.VT3989 is a TEAD inhibitor. It works by blocking…
In July 2020, the Mesothelioma UK Research Centre was established at the University of Sheffield, thanks to funding from the national charity, Mesothelioma UK. The center brings together researchers, clinicians, and PhD students, all experts in mesothelioma, to improve the care and quality of life for people living with this…
Dear Members of the Meso Community, We understand the deep concern many of you are feeling regarding the current changes and fluctuations in funding for federal programs. The mesothelioma community is tied into federal programming in a few ways, but the two main ones are: Patient services, clinical trials, and research through…
Caregivers of mesothelioma patients perform crucial duties and bear considerable burdens after a loved one’s diagnosis of mesothelioma. While resources for patients are often available at treatment centers and through organizations like the Mesothelioma Applied Research Foundation, caregivers report a lack of support. Understanding and identifying the needs of caregivers…
As we dive into 2025, we want to bring new and exciting patient services and educational pieces to the mesothelioma community. We’re excited to announce the launch of our new monthly zoom series, 2025 Spotlight Sessions. Each session is designed to bring a relevant, insightful, and empowering discussion to the community.…
On this episode of MesoTV, our Patients Services Director, Julie White, RN, BSN, OCN, sits down with our new Executive Director, Brian Lepacek, MDiv, CAE, to discuss his role and how he got to the foundation. If you haven’t met Brian yet, definitely check out this episode to get to…
CAR-T (Chimeric antigen receptor) cell therapy is a type of immunotherapy that uses a patient’s T cells to attack cancer cells. T cells are white blood cells that fight infection and illness, but cancer cells can sometimes trick the immune system. CAR T-cell therapy helps the body’s immune system see…
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with pemetrexed and platinum-based chemotherapy. Keytruda(pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help…
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free…
